EMEA-000480-PIP01-08-M13

Key facts

Invented name
Brilique
Active substance
ticagrelor
Therapeutic area
  • Cardiovascular diseases
  • Haematology-Hemostaseology
Decision number
P/0217/2020
PIP number
EMEA-000480-PIP01-08-M13
Pharmaceutical form(s)
  • Film-coated tablet
  • Granules for oral suspension
  • Orodispersible tablet
Condition(s) / indication(s)
Prevention of thromboembolic events
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

Tel. +46 8553 27591
E-mail: paediatrics@astrazeneca.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating